International review of cell and molecular biology最新文献_第5页

Inflammatory breast cancer (IBC) advocacy-Past, present and future! 炎症性乳腺癌（IBC）宣传--过去、现在和未来！

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2023-11-21 DOI: 10.1016/bs.ircmb.2023.11.001

Jeannine Donahue, Joshlyn Earls, Valerie Fraser, Ginny Mason, Heather Pirowski, Peggy Stephens

{"title":"Inflammatory breast cancer (IBC) advocacy-Past, present and future!","authors":"Jeannine Donahue, Joshlyn Earls, Valerie Fraser, Ginny Mason, Heather Pirowski, Peggy Stephens","doi":"10.1016/bs.ircmb.2023.11.001","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2023.11.001","url":null,"abstract":"Patient advocates, referring to those individuals that have been diagnosed with the disease for which they advocate, are essential stake holders in healthcare. For those facing the stages of being diagnosed with Inflammatory Breast Cancer (IBC), the \"call to advocate\" is an immediate response to being diagnosed with a rare and aggressive disease that progresses rapidly, often in a matter of weeks or months. There is a great stigma and bias in the medical community that has inhibited the education and study of IBC. A lack of understanding of the disease, how it presents and how to treat it leaves many IBC patients facing misdiagnosis. Communication is a cornerstone of healthcare; this goes beyond the patient-provider dynamic. Education of IBC must be a grassroots initiative. There should be no barrier to care in the diagnosis, treatment, study and survivorship of inflammatory Breast Cancer. It is not just an oncologist's lesson to learn, but that of all providers in healthcare. In this chapter you will hear how 4 women who were diagnosed with IBC faced the difficult tasks of navigating through the healthcare system on their own and came out on the other side using their experience to help others. In conclusion, in defining the evolving roles of Patient Advocacy in IBC over the past 25 years, we examine what has been done, along with its challenges, and what work still remains from the perspectives of different patient advocates.","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of interferon dependent and independent signaling pathways: Implications in cancer. 干扰素依赖和独立信号通路的作用：对癌症的影响

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2024-08-02 DOI: 10.1016/bs.ircmb.2024.06.004

Sheila Spada, Anirban Ganguly

引用次数: 0

Exploring TLR signaling pathways as promising targets in cervical cancer: The road less traveled. 将 TLR 信号通路作为宫颈癌的有望靶点进行探索：少有人走的路

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2024-01-12 DOI: 10.1016/bs.ircmb.2023.11.005

Mohini Agarwal, Manish Kumar, Rajiv Pathak, Kumud Bala, Anoop Kumar

{"title":"Exploring TLR signaling pathways as promising targets in cervical cancer: The road less traveled.","authors":"Mohini Agarwal, Manish Kumar, Rajiv Pathak, Kumud Bala, Anoop Kumar","doi":"10.1016/bs.ircmb.2023.11.005","DOIUrl":"10.1016/bs.ircmb.2023.11.005","url":null,"abstract":"Cervical cancer is the leading cause of cancer-related deaths for women globally. Despite notable advancements in prevention and treatment, the identification of novel therapeutic targets remains crucial for cervical cancer. Toll-like receptors (TLRs) play an essential role in innate immunity as pattern-recognition receptors. There are several types of pathogen-associated molecular patterns (PAMPs), including those present in cervical cancer cells, which have the ability to activate toll-like receptors (TLRs). Recent studies have revealed dysregulated toll-like receptor (TLR) signaling pathways in cervical cancer, leading to the production of inflammatory cytokines and chemokines that can facilitate tumor growth and metastasis. Consequently, TLRs hold significant promise as potential targets for innovative therapeutic agents against cervical cancer. This book chapter explores the role of TLR signaling pathways in cervical cancer, highlighting their potential for targeted therapy while addressing challenges such as tumor heterogeneity and off-target effects. Despite these obstacles, targeting TLR signaling pathways presents a promising approach for the development of novel and effective treatments for cervical cancer.","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitochondria driven innate immune signaling and inflammation in cancer growth, immune evasion, and therapeutic resistance. 线粒体驱动的先天性免疫信号传导和炎症在癌症生长、免疫逃避和治疗抵抗中的作用。

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2024-03-13 DOI: 10.1016/bs.ircmb.2024.01.006

Sanjay Pandey, Vandana Anang, Michelle M Schumacher

{"title":"Mitochondria driven innate immune signaling and inflammation in cancer growth, immune evasion, and therapeutic resistance.","authors":"Sanjay Pandey, Vandana Anang, Michelle M Schumacher","doi":"10.1016/bs.ircmb.2024.01.006","DOIUrl":"10.1016/bs.ircmb.2024.01.006","url":null,"abstract":"Mitochondria play an important and multifaceted role in cellular function, catering to the cell's energy and biosynthetic requirements. They modulate apoptosis while responding to diverse extracellular and intracellular stresses including reactive oxygen species (ROS), nutrient and oxygen scarcity, endoplasmic reticulum stress, and signaling via surface death receptors. Integral components of mitochondria, such as mitochondrial DNA (mtDNA), mitochondrial RNA (mtRNA), Adenosine triphosphate (ATP), cardiolipin, and formyl peptides serve as major damage-associated molecular patterns (DAMPs). These molecules activate multiple innate immune pathways both in the cytosol [such as Retionoic Acid-Inducible Gene-1 (RIG-1) and Cyclic GMP-AMP Synthase (cGAS)] and on the cell surface [including Toll-like receptors (TLRs)]. This activation cascade leads to the release of various cytokines, chemokines, interferons, and other inflammatory molecules and oxidative species. The innate immune pathways further induce chronic inflammation in the tumor microenvironment which either promotes survival and proliferation or promotes epithelial to mesenchymal transition (EMT), metastasis and therapeutic resistance in the cancer cell's. Chronic activation of innate inflammatory pathways in tumors also drives immunosuppressive checkpoint expression in the cancer cells and boosts the influx of immune-suppressive populations like Myeloid-Derived Suppressor Cells (MDSCs) and Regulatory T cells (Tregs) in cancer. Thus, sensing of cellular stress by the mitochondria may lead to enhanced tumor growth. In addition to that, the tumor microenvironment also becomes a source of immunosuppressive cytokines. These cytokines exert a debilitating effect on the functioning of immune effector cells, and thus foster immune tolerance and facilitate immune evasion. Here we describe how alteration of the mitochondrial homeostasis and cellular stress drives innate inflammatory pathways in the tumor microenvironment.","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients. 健康与疾病中的免疫检查点生物学：免疫检查点生物学与癌症患者的自身免疫。

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2023-05-24 DOI: 10.1016/bs.ircmb.2023.04.003

Pierre Van Mol, Elena Donders, Diether Lambrechts, Els Wauters

引用次数: 0

Novel technologies for applying immune checkpoint blockers. 应用免疫检查点阻断剂的新技术。

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2023-03-30 DOI: 10.1016/bs.ircmb.2023.03.003

Robin Maximilian Awad, Karine Breckpot

引用次数: 0

Inflammatory breast cancer: As surgical oncologists, what can we do? 炎症性乳腺癌：作为外科肿瘤学家，我们能做些什么？

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2024-03-28 DOI: 10.1016/bs.ircmb.2024.02.004

Hatem Bouzaiene, Fatma Saadallah, Hanen Bouaziz, Olfa Jaidane, Jamel Ben Hassouna, Tarak Dhieb, Khaled Rahal

{"title":"Inflammatory breast cancer: As surgical oncologists, what can we do?","authors":"Hatem Bouzaiene, Fatma Saadallah, Hanen Bouaziz, Olfa Jaidane, Jamel Ben Hassouna, Tarak Dhieb, Khaled Rahal","doi":"10.1016/bs.ircmb.2024.02.004","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2024.02.004","url":null,"abstract":"Breast cancer surgery is the primary treatment for early-stage breast cancer. However, inflammatory breast cancer (IBC), with its specific presentation characterized by skin invasion, is unfit for primary surgery. According to the different guidelines, the management of IBC is trimodal with the coordination of oncologists, surgeons, and radiation therapists. Advances in breast cancer imaging and the development of more targeted therapies make new challenges for this aggressive cancer. This chapter aims to provide an update on the role of surgery in IBC. Radical surgery is still considered the standard surgical treatment in IBC. Some authors suggest a conservative surgery in patients with a clinical response to chemotherapy without affecting survival. For lymph node surgery, the sentinel lymph node biopsy (SLNB) is not feasible in IBC patients, according to the existing studies. However, prospective studies on SLNB are needed to verify its reliability after chemotherapy for a specific group of patients. In the metastatic IBC, surgery can be considered if there is a good response after chemotherapy or for uncontrolled symptoms. Existing studies showed that surgery may impact survival for these patients. Prospective studies are mandatory to optimize IBC management, considering factors such as tumor's molecular profile.","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140848539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in targets in inflammatory breast cancer. 炎症性乳腺癌靶点研究进展。

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2024-02-05 DOI: 10.1016/bs.ircmb.2023.10.005

Toshiaki Iwase, Xiaoping Wang, Lan Thi Hanh Phi, Nithya Sridhar, Naoto T Ueno, Jangsoon Lee

引用次数: 0

Epigenetic contribution to the relationship between obesity and cancer. 表观遗传学对肥胖与癌症之间关系的贡献。

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2024-05-14 DOI: 10.1016/bs.ircmb.2024.03.007

Yen-Vy Nguyen Thi, Thuy-Duong Vu, Nguyen Thi Lan Huong, Dinh-Toi Chu

{"title":"Epigenetic contribution to the relationship between obesity and cancer.","authors":"Yen-Vy Nguyen Thi, Thuy-Duong Vu, Nguyen Thi Lan Huong, Dinh-Toi Chu","doi":"10.1016/bs.ircmb.2024.03.007","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2024.03.007","url":null,"abstract":"Obesity and cancer are two major health issues all around the world due to their elevated prevalence. Several experimental and epidemiological studies have demonstrated the relationship between obesity and cancer, in which obesity is considered a risk factor for cancer development. The ultimate goal of knowing the epigenetic contribution to the relationship between obesity and cancer is to find the method of intervention or treatment of obesity and cancer. Therefore, providing the most general perspective on epigenetic contribution to the relationship between obesity and cancer is necessary. Obesity is closely related to some common cancers that are currently encountered, including breast, esophagus, liver, kidney, uterus, colorectal, pancreatic, and gallbladder. Obesity has a significant impact that increases the risk of cancer deaths and thereby indirectly affects the choice of treatment. It is estimated that about 4-8% of cancer cases are caused by obesity. In particular, the basic mechanism to understand the relationship between cancer is very complicated and has not been fully understood. This work is aimed at summarizing the current knowledge of the role of epigenetic regulation in the relationship between obesity, and potential applications.","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetic contribution to cancer. 表观遗传对癌症的影响

3区生物学

International review of cell and molecular biology Pub Date : 2024-01-01 Epub Date: 2024-06-19 DOI: 10.1016/bs.ircmb.2024.05.003

Songhua Quan, Hao Huang

{"title":"Epigenetic contribution to cancer.","authors":"Songhua Quan, Hao Huang","doi":"10.1016/bs.ircmb.2024.05.003","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2024.05.003","url":null,"abstract":"Epigenetics has transformed our understanding of cancer by revealing how changes in gene activity, which do not alter the DNA itself, can initiate and progress the disease. These changes include adjustments in DNA methylation, histone configuration, and non-coding RNA activity. For instance, DNA methylation can inactivate genes that typically protect against cancer, leading to broader genomic instability. Histone modifications can alter how tightly DNA is wound, influencing which genes are active or silenced; while non-coding RNAs can interfere with the messages that direct protein production, impacting cancer-related processes. Unlike genetic mutations, which are permanent and irreversible, epigenetic changes provide a malleable target for therapeutic intervention, allowing potentially reversible adjustments to gene expression patterns. This flexibility is essential in the complex landscape of cancer where static genetic solutions may be insufficient. Additionally, epigenetics bridges the gap between genetic predispositions and environmental influences on cancer, offering a comprehensive framework for understanding how lifestyle factors and external exposures impact cancer risk and progression. The integration of epigenetics into cancer research not only enhances our understanding of the disease but also opens innovative avenues for intervention that were previously unexplored in traditional genetic-focused studies. Technologies like advanced sequencing and precise epigenetic modification are paving the way for early cancer detection and more personalized treatment approaches, highlighting the critical role of epigenetics in modern cancer care.","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0